Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature
: Myelin oligodendrocyte glycoprotein (MOG) is exclusively expressed in the central nervous system (CNS) and is found on the outer surface of oligodendrocytes. Antibodies to MOG are associated with CNS demyelination, whereas peripheral nervous system (PNS) demyelination is seldom reported to be rela...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2024-06, Vol.13 (12), p.3604 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 3604 |
| container_title | Journal of clinical medicine |
| container_volume | 13 |
| creator | Papadopoulou, Marianna Tzanetakos, Dimitrios Moschovos, Christos Korona, Anastasia Vartzelis, George Voudris, Konstantinos Fanouraki, Stella Dimitriadou, Evangelia-Makrina Papadimas, Georgios Tzartos, John S Giannopoulos, Sotirios Tsivgoulis, Georgios |
| description | : Myelin oligodendrocyte glycoprotein (MOG) is exclusively expressed in the central nervous system (CNS) and is found on the outer surface of oligodendrocytes. Antibodies to MOG are associated with CNS demyelination, whereas peripheral nervous system (PNS) demyelination is seldom reported to be related to MOG-IgG.
: The database of patients seen in our neurological academic center was searched for MOG-IgG seropositivity and concomitant demyelinating polyneuropathy. For the purpose of the review, in March 2024, we searched for case reports and case series in the following databases: PubMed, Scopus, Cochrane, and ScienceDirect. Inclusion criteria were MOG-IgG seropositivity and demyelinating polyneuropathy. Exclusion criteria were type of publication other than case reports and case series, unconfirmed diagnosis of demyelinating polyneuropathy, and other diseases causing demyelination in either the CNS or PNS. Critical appraisal of the selected case reports and case series was realized by JBI.
: Four new cases were identified with MOG-IgG and confirmed demyelinating polyneuropathy. This review identified 22 cases that have been published since 2018. Clinical, imaging, neurophysiological, and immunological characteristics, as well as treatment options and outcomes are presented and compared to those of other cases with combined central and peripheral demyelination (CCPD).
: The pathogenetic mechanism is unclear; thus, different hypotheses are discussed. New case reporting and large cohort studies will help further the exploration of the underlying mechanism and guide more effective therapeutic interventions. |
| doi_str_mv | 10.3390/jcm13123604 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11204739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A799634890</galeid><sourcerecordid>A799634890</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-42306b5bb383b2e6278dff4d54e3dcd03d98b69916e190afdcf41bd125bfa9443</originalsourceid><addsrcrecordid>eNptkktvEzEQx1cIRKvSE3dkiUsRSvFrH-aCou0DpNBWCM6WvZ5tHO3aqe2k6vfgA9dpSkkR9sGP-c1_NH9NUbwl-JgxgT8tupEwQlmF-Ytin-K6nmDWsJc7973iMMYFzqtpOCX162KPNYJhwul-8bv1o7YODGrBpaAGpJxBVxDscg6b5wmMdzBYp5L1Dh217dXJBzSN0XdWpZx2a9Mcfb88R1OXrPbGQvyMfsDSh4R8j878KqALuEWtihAfxC9UCFltDRlb2xzKWJoDmtmUK6ZVgDfFq14NEQ4fz4Pi19npz_brZHZ5_q2dziYdq8o04ZThSpda5yY1hYrWjel7bkoOzHQGMyMaXQlBKiACq950PSfaEFrqXgnO2UHxZau7XOkRTLd1QC6DHVW4k15Z-Tzi7Fxe-7UkhGJeM5EVjh4Vgr9ZQUxytLGDYVAO_CpKhmva4Kasm4y-_wddZG9c7u-BYiWuRf2XulYDSOt6nwt3G1E5rYWoGG8EztTxf6i8DYy28w56m_-fJXzcJnTBxxigf2qSYLkZJLkzSJl-t-vLE_tnbNg9-TzCqw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3072350797</pqid></control><display><type>article</type><title>Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Papadopoulou, Marianna ; Tzanetakos, Dimitrios ; Moschovos, Christos ; Korona, Anastasia ; Vartzelis, George ; Voudris, Konstantinos ; Fanouraki, Stella ; Dimitriadou, Evangelia-Makrina ; Papadimas, Georgios ; Tzartos, John S ; Giannopoulos, Sotirios ; Tsivgoulis, Georgios</creator><creatorcontrib>Papadopoulou, Marianna ; Tzanetakos, Dimitrios ; Moschovos, Christos ; Korona, Anastasia ; Vartzelis, George ; Voudris, Konstantinos ; Fanouraki, Stella ; Dimitriadou, Evangelia-Makrina ; Papadimas, Georgios ; Tzartos, John S ; Giannopoulos, Sotirios ; Tsivgoulis, Georgios</creatorcontrib><description>: Myelin oligodendrocyte glycoprotein (MOG) is exclusively expressed in the central nervous system (CNS) and is found on the outer surface of oligodendrocytes. Antibodies to MOG are associated with CNS demyelination, whereas peripheral nervous system (PNS) demyelination is seldom reported to be related to MOG-IgG.
: The database of patients seen in our neurological academic center was searched for MOG-IgG seropositivity and concomitant demyelinating polyneuropathy. For the purpose of the review, in March 2024, we searched for case reports and case series in the following databases: PubMed, Scopus, Cochrane, and ScienceDirect. Inclusion criteria were MOG-IgG seropositivity and demyelinating polyneuropathy. Exclusion criteria were type of publication other than case reports and case series, unconfirmed diagnosis of demyelinating polyneuropathy, and other diseases causing demyelination in either the CNS or PNS. Critical appraisal of the selected case reports and case series was realized by JBI.
: Four new cases were identified with MOG-IgG and confirmed demyelinating polyneuropathy. This review identified 22 cases that have been published since 2018. Clinical, imaging, neurophysiological, and immunological characteristics, as well as treatment options and outcomes are presented and compared to those of other cases with combined central and peripheral demyelination (CCPD).
: The pathogenetic mechanism is unclear; thus, different hypotheses are discussed. New case reporting and large cohort studies will help further the exploration of the underlying mechanism and guide more effective therapeutic interventions.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13123604</identifier><identifier>PMID: 38930142</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Analysis ; Antibodies ; Antigens ; B cells ; Care and treatment ; Demyelinating diseases ; Diagnosis ; Disease ; Etiology ; Glycoproteins ; Health aspects ; Inflammation ; Nervous system ; Neurophysiology ; Proteins ; Spinal cord ; Systematic Review ; Testing ; Viral antibodies</subject><ispartof>Journal of clinical medicine, 2024-06, Vol.13 (12), p.3604</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c365t-42306b5bb383b2e6278dff4d54e3dcd03d98b69916e190afdcf41bd125bfa9443</cites><orcidid>0000-0001-8925-3327 ; 0000-0002-0640-3797 ; 0000-0002-0163-7455 ; 0000-0003-0163-4091 ; 0000-0001-7443-5179</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204739/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204739/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38930142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papadopoulou, Marianna</creatorcontrib><creatorcontrib>Tzanetakos, Dimitrios</creatorcontrib><creatorcontrib>Moschovos, Christos</creatorcontrib><creatorcontrib>Korona, Anastasia</creatorcontrib><creatorcontrib>Vartzelis, George</creatorcontrib><creatorcontrib>Voudris, Konstantinos</creatorcontrib><creatorcontrib>Fanouraki, Stella</creatorcontrib><creatorcontrib>Dimitriadou, Evangelia-Makrina</creatorcontrib><creatorcontrib>Papadimas, Georgios</creatorcontrib><creatorcontrib>Tzartos, John S</creatorcontrib><creatorcontrib>Giannopoulos, Sotirios</creatorcontrib><creatorcontrib>Tsivgoulis, Georgios</creatorcontrib><title>Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>: Myelin oligodendrocyte glycoprotein (MOG) is exclusively expressed in the central nervous system (CNS) and is found on the outer surface of oligodendrocytes. Antibodies to MOG are associated with CNS demyelination, whereas peripheral nervous system (PNS) demyelination is seldom reported to be related to MOG-IgG.
: The database of patients seen in our neurological academic center was searched for MOG-IgG seropositivity and concomitant demyelinating polyneuropathy. For the purpose of the review, in March 2024, we searched for case reports and case series in the following databases: PubMed, Scopus, Cochrane, and ScienceDirect. Inclusion criteria were MOG-IgG seropositivity and demyelinating polyneuropathy. Exclusion criteria were type of publication other than case reports and case series, unconfirmed diagnosis of demyelinating polyneuropathy, and other diseases causing demyelination in either the CNS or PNS. Critical appraisal of the selected case reports and case series was realized by JBI.
: Four new cases were identified with MOG-IgG and confirmed demyelinating polyneuropathy. This review identified 22 cases that have been published since 2018. Clinical, imaging, neurophysiological, and immunological characteristics, as well as treatment options and outcomes are presented and compared to those of other cases with combined central and peripheral demyelination (CCPD).
: The pathogenetic mechanism is unclear; thus, different hypotheses are discussed. New case reporting and large cohort studies will help further the exploration of the underlying mechanism and guide more effective therapeutic interventions.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>B cells</subject><subject>Care and treatment</subject><subject>Demyelinating diseases</subject><subject>Diagnosis</subject><subject>Disease</subject><subject>Etiology</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Inflammation</subject><subject>Nervous system</subject><subject>Neurophysiology</subject><subject>Proteins</subject><subject>Spinal cord</subject><subject>Systematic Review</subject><subject>Testing</subject><subject>Viral antibodies</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkktvEzEQx1cIRKvSE3dkiUsRSvFrH-aCou0DpNBWCM6WvZ5tHO3aqe2k6vfgA9dpSkkR9sGP-c1_NH9NUbwl-JgxgT8tupEwQlmF-Ytin-K6nmDWsJc7973iMMYFzqtpOCX162KPNYJhwul-8bv1o7YODGrBpaAGpJxBVxDscg6b5wmMdzBYp5L1Dh217dXJBzSN0XdWpZx2a9Mcfb88R1OXrPbGQvyMfsDSh4R8j878KqALuEWtihAfxC9UCFltDRlb2xzKWJoDmtmUK6ZVgDfFq14NEQ4fz4Pi19npz_brZHZ5_q2dziYdq8o04ZThSpda5yY1hYrWjel7bkoOzHQGMyMaXQlBKiACq950PSfaEFrqXgnO2UHxZau7XOkRTLd1QC6DHVW4k15Z-Tzi7Fxe-7UkhGJeM5EVjh4Vgr9ZQUxytLGDYVAO_CpKhmva4Kasm4y-_wddZG9c7u-BYiWuRf2XulYDSOt6nwt3G1E5rYWoGG8EztTxf6i8DYy28w56m_-fJXzcJnTBxxigf2qSYLkZJLkzSJl-t-vLE_tnbNg9-TzCqw</recordid><startdate>20240620</startdate><enddate>20240620</enddate><creator>Papadopoulou, Marianna</creator><creator>Tzanetakos, Dimitrios</creator><creator>Moschovos, Christos</creator><creator>Korona, Anastasia</creator><creator>Vartzelis, George</creator><creator>Voudris, Konstantinos</creator><creator>Fanouraki, Stella</creator><creator>Dimitriadou, Evangelia-Makrina</creator><creator>Papadimas, Georgios</creator><creator>Tzartos, John S</creator><creator>Giannopoulos, Sotirios</creator><creator>Tsivgoulis, Georgios</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8925-3327</orcidid><orcidid>https://orcid.org/0000-0002-0640-3797</orcidid><orcidid>https://orcid.org/0000-0002-0163-7455</orcidid><orcidid>https://orcid.org/0000-0003-0163-4091</orcidid><orcidid>https://orcid.org/0000-0001-7443-5179</orcidid></search><sort><creationdate>20240620</creationdate><title>Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature</title><author>Papadopoulou, Marianna ; Tzanetakos, Dimitrios ; Moschovos, Christos ; Korona, Anastasia ; Vartzelis, George ; Voudris, Konstantinos ; Fanouraki, Stella ; Dimitriadou, Evangelia-Makrina ; Papadimas, Georgios ; Tzartos, John S ; Giannopoulos, Sotirios ; Tsivgoulis, Georgios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-42306b5bb383b2e6278dff4d54e3dcd03d98b69916e190afdcf41bd125bfa9443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>B cells</topic><topic>Care and treatment</topic><topic>Demyelinating diseases</topic><topic>Diagnosis</topic><topic>Disease</topic><topic>Etiology</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Inflammation</topic><topic>Nervous system</topic><topic>Neurophysiology</topic><topic>Proteins</topic><topic>Spinal cord</topic><topic>Systematic Review</topic><topic>Testing</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papadopoulou, Marianna</creatorcontrib><creatorcontrib>Tzanetakos, Dimitrios</creatorcontrib><creatorcontrib>Moschovos, Christos</creatorcontrib><creatorcontrib>Korona, Anastasia</creatorcontrib><creatorcontrib>Vartzelis, George</creatorcontrib><creatorcontrib>Voudris, Konstantinos</creatorcontrib><creatorcontrib>Fanouraki, Stella</creatorcontrib><creatorcontrib>Dimitriadou, Evangelia-Makrina</creatorcontrib><creatorcontrib>Papadimas, Georgios</creatorcontrib><creatorcontrib>Tzartos, John S</creatorcontrib><creatorcontrib>Giannopoulos, Sotirios</creatorcontrib><creatorcontrib>Tsivgoulis, Georgios</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papadopoulou, Marianna</au><au>Tzanetakos, Dimitrios</au><au>Moschovos, Christos</au><au>Korona, Anastasia</au><au>Vartzelis, George</au><au>Voudris, Konstantinos</au><au>Fanouraki, Stella</au><au>Dimitriadou, Evangelia-Makrina</au><au>Papadimas, Georgios</au><au>Tzartos, John S</au><au>Giannopoulos, Sotirios</au><au>Tsivgoulis, Georgios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-06-20</date><risdate>2024</risdate><volume>13</volume><issue>12</issue><spage>3604</spage><pages>3604-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>: Myelin oligodendrocyte glycoprotein (MOG) is exclusively expressed in the central nervous system (CNS) and is found on the outer surface of oligodendrocytes. Antibodies to MOG are associated with CNS demyelination, whereas peripheral nervous system (PNS) demyelination is seldom reported to be related to MOG-IgG.
: The database of patients seen in our neurological academic center was searched for MOG-IgG seropositivity and concomitant demyelinating polyneuropathy. For the purpose of the review, in March 2024, we searched for case reports and case series in the following databases: PubMed, Scopus, Cochrane, and ScienceDirect. Inclusion criteria were MOG-IgG seropositivity and demyelinating polyneuropathy. Exclusion criteria were type of publication other than case reports and case series, unconfirmed diagnosis of demyelinating polyneuropathy, and other diseases causing demyelination in either the CNS or PNS. Critical appraisal of the selected case reports and case series was realized by JBI.
: Four new cases were identified with MOG-IgG and confirmed demyelinating polyneuropathy. This review identified 22 cases that have been published since 2018. Clinical, imaging, neurophysiological, and immunological characteristics, as well as treatment options and outcomes are presented and compared to those of other cases with combined central and peripheral demyelination (CCPD).
: The pathogenetic mechanism is unclear; thus, different hypotheses are discussed. New case reporting and large cohort studies will help further the exploration of the underlying mechanism and guide more effective therapeutic interventions.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38930142</pmid><doi>10.3390/jcm13123604</doi><orcidid>https://orcid.org/0000-0001-8925-3327</orcidid><orcidid>https://orcid.org/0000-0002-0640-3797</orcidid><orcidid>https://orcid.org/0000-0002-0163-7455</orcidid><orcidid>https://orcid.org/0000-0003-0163-4091</orcidid><orcidid>https://orcid.org/0000-0001-7443-5179</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2024-06, Vol.13 (12), p.3604 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11204739 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analysis Antibodies Antigens B cells Care and treatment Demyelinating diseases Diagnosis Disease Etiology Glycoproteins Health aspects Inflammation Nervous system Neurophysiology Proteins Spinal cord Systematic Review Testing Viral antibodies |
| title | Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A03%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20Central%20and%20Peripheral%20Demyelination%20(CCPD)%20Associated%20with%20MOG%20Antibodies:%20Report%20of%20Four%20New%20Cases%20and%20Narrative%20Review%20of%20the%20Literature&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Papadopoulou,%20Marianna&rft.date=2024-06-20&rft.volume=13&rft.issue=12&rft.spage=3604&rft.pages=3604-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13123604&rft_dat=%3Cgale_pubme%3EA799634890%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3072350797&rft_id=info:pmid/38930142&rft_galeid=A799634890&rfr_iscdi=true |